EQT AB (0AAZ)
London Exchange · UK · prices in SEK · close of 21 Oct 2026
Key indicators
| Last close | SEK 293.35 |
|---|---|
| 52-week range | 259.25 – 378.61 |
| Return, 1 month / 3 months | −2.8% / −5.6% |
| Return, 1 year / 3 years | −9.9% / +39.4% |
| Trend | Below its 200-day average |
| RSI (14) | 49 |
| Volatility (1 year) | 35.6% |
| Worst drawdown (1 year) | -29.9% |
| Average daily value traded | 103.98M SEK |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
EQT AB is a Swedish investment firm based in Stockholm that raises and manages private equity, infrastructure, real estate and credit funds. Its funds take stakes in companies across sectors and work with their management teams to develop the businesses over time. The firm's investors are mainly institutional clients such as pension funds, insurance companies and other long-term investors, and it also runs investment operations from offices in several countries.
The shares are listed on the London Exchange in UK under the code 0AAZ, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
EQT AB (0AAZ) trades on the London Exchange in UK. It last closed at SEK 293.35 on 21 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 2,099 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 9.9% and over the last three months it fell 5.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 43 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.0% | ||
| From 52-week high | -21.4% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.6% | ||
| 6-month return | -7.9% | ||
| 12-month return, skipping the last month | -7.3% | ||
| Stability (higher is calmer) | 49 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.9% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 103.98M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 48 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.8% |
|---|---|
| 1 month | −2.8% |
| 3 months | −5.6% |
| 6 months | −7.9% |
| 1 year | −9.9% |
| 3 years | +39.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 308.20 / 305.44 |
|---|---|
| Golden / death cross (60 days) | Golden, 37 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | SEK 2.5000 |
| 28 Nov 2025 | SEK 2.1500 |
| 28 May 2025 | SEK 2.1500 |
| 29 Nov 2024 | SEK 1.8000 |
| 28 May 2024 | SEK 1.8000 |
| 29 Nov 2023 | SEK 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.